key: cord-0919846-0p5fjx6c authors: Lu, Lu; Mok, Bobo Wing-Yee; Chen, Lin-Lei; Chan, Jacky Man-Chun; Tsang, Owen Tak-Yin; Lam, Bosco Hoi-Shiu; Chuang, Vivien Wai-Man; Chu, Allen Wing-Ho; Chan, Wan-Mui; Ip, Jonathan Daniel; Chan, Brian Pui-Chun; Zhang, Ruiqi; Yip, Cyril Chik-Yan; Cheng, Vincent Chi-Chung; Chan, Kwok-Hung; Jin, Dong-Yan; Hung, Ivan Fan-Ngai; Yuen, Kwok-Yung; Chen, Honglin; To, Kelvin Kai-Wang title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients date: 2021-12-16 journal: Clin Infect Dis DOI: 10.1093/cid/ciab1041 sha: 2dfedc6475816a350d9487afdaec1e90f9d12763 doc_id: 919846 cord_uid: 0p5fjx6c BACKGROUND: The SARS-CoV-2 Omicron variant, designated as a Variant of Concern(VOC) by the World Health Organization, carries numerous spike mutations which have are known to evade neutralizing antibodies elicited by COVID-19 vaccines. A deeper understanding of the susceptibility of Omicron variant to vaccine-induced neutralizing antibodies is urgently needed for risk assessment. METHODS: Omicron variant strains HKU691 and HKU344-R346K were isolated from patients using TMPRSS2-overexpressing VeroE6 cells. Whole genome sequence was determined using nanopore sequencing. Neutralization susceptibility of ancestral lineage A virus and the Omicron, Delta and Beta variants to sera from 25 BNT162b2 and 25 Coronavac vaccine recipients was determined using a live virus microneutralization assay. RESULTS: The Omicron variant strain HKU344-R346K has an additional spike R346K mutation, which is present in 8.5% of strains deposited in GISAID database. Only 20% and 24% of BNT162b2 recipients had detectable neutralizing antibody against the Omicron variant HKU691 and HKU344-R346K, respectively, while none of the Coronavac recipients had detectable neutralizing antibody titer against either Omicron isolate. For BNT162b2 recipients, the geometric mean neutralization antibody titers(GMT) of the Omicron variant isolates(5.43 and 6.42) were 35.7-39.9-fold lower than that of the ancestral virus(229.4), and the GMT of both Omicron variant isolates were significantly lower than those of the Beta and Delta variants. There was no significant difference in the GMT between HKU691 and HKU344-R346K. CONCLUSIONS: Omicron variant escapes neutralizing antibodies elicited by BNT162b2 or Coronavac. The additional R346K mutation did not affect the neutralization susceptibility. Our data suggest that the Omicron variant may be associated with lower COVID-19 vaccine effectiveness. A c c e p t e d M a n u s c r i p t The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmits efficiently among the human population [1] . Airborne transmission of SARS-CoV-2 within hospitals has been reported [2] . Stringent public health and social measures have been implemented worldwide in an effort to control the Coronavirus Disease 2019 (COVID- 19) pandemic [3] . The availability of COVID-19 vaccine since late 2020 has offered hope that the [4] . However, several variants with mutations in the spike protein receptor binding domain (RBD), especially at the receptor binding motif (RBM), have emerged and have been found to escape neutralization from antibodies in patients recovered from COVID-19 infection or vaccine recipients [5, 6] . These variants, especially the Beta, Gamma and Delta variants, have been associated with reduced vaccine effectiveness [7] . On between two travelers who were quarantined at a hotel in Hong Kong [8] . Preliminary data from South Africa suggest that the emergence of Omicron variant is associated with a higher A c c e p t e d M a n u s c r i p t 6 risk of reinfection [9] and a faster doubling time [10] . Preliminary findings from the United Kingdom suggest that the Omicron variant is associated with a higher risk of transmission among household contacts than that of the Delta variant [11] . Because of the large number of mutations, especially at the spike RBD, there is a concern that the Omicron variant can escape antibody neutralization induced by the current generation COVID-19 vaccines. Here, we determined the neutralization susceptibility of two Omicron variant isolates to antibodies from COVID-19 vaccine recipients, and compared it to the ancestral SARS-CoV-2 lineage A virus, the Beta variant, and the Delta variant. The Viral culture was performed in a biosafety level 3 facility as we described previously [6] . Briefly, TMPRSS2-expressing VeroE6 (VeroE6/TMPRSS2) cells (JCRB Cat#JCRB1819) were seeded with 100 L of minimum essential medium (MEM) (Thermo A c c e p t e d M a n u s c r i p t 7 Fisher Scientific) at 4 x 10 4 cells/mL in 96-well plate and incubated at 37°C in a carbon dioxide incubator until confluence for inoculation. Each well was inoculated with 30 L of clinical specimen. Virus-induced cytopathic effect was examined. Cultures with more than 50% virus-induced cytopathic effect were expanded to large volume and 50% tissue culture infective doses (TCID 50 ) were determined. The whole genome sequence of the culture isolates was determined using nanopore sequencing (Oxford Nanopore Technologies). Purified libraries were sequenced with the Oxford Nanopore MinION device using R9.4.1 flow cells. We described the lineage information using the Pangolin nomenclatures [13] . Live virus MN assay was performed as we described previously [6] . This study included serum specimens from a total of 50 adult vaccine recipients, of whom 25 received BNT162b2 and 25 received the Coronavac. The median age was 48 years, with an interquartile range of 40 to 54 years (Table 1 ). There was no statistically significant difference in the age, sex, or comorbidites between the BNT162b2 and Coronavac groups. All individuals have received two doses of COVID-19 vaccines, and the serum specimens were collected 56 days after the first dose of vaccine. We included 2 Omicron variant culture isolates (HKU691 and HKU344-R346K) in this study. Both isolates belong to the Pangolin BA.1 lineage. These two virus isolates differ by only 2 nucleotides ( and HKU344-R346K (6.42) was 39.9-and 35.7-fold lower than those of the ancestral lineage A virus (229.4), respectively (P <0.0001) (Figure 1 ; Table 3 ). The GMT against both Omicron variant isolates were also significantly lower than those against the Beta variant Our results corroborate with the results from recent preprint articles. Cele et al showed that the neutralization titer is 41-fold lower than that of a D614G virus [14] . In another study, Cao et al used pseudovirus neutralization assay and yeast-display RBD library to demonstrate that the Omicron variant can escape from neutralizing monoclonal antibodies [15] . Our study is unique in 2 different ways. First, we tested serum from Coronavac recipients. This is especially important because Coronavac is widely used globally. Second, we included an Omicron variant with R346K mutation. The R346K mutation is a particular concern because the spike R346K mutation is located within the RBD. R346K mutation is also present in the Mu variant, which has been shown to be least susceptible to sera from COVID-19 vaccine recipients [16] . The spike amino acid residue 346 is located in the epitope of a class 3 monoclonal neutralizing antibody C135 [17] , and escape mutants during C135 passage contains the R346K mutation [18] . Neutralizing antibody titer correlated with vaccine protection in clinical trials and in animal studies [19, 20] . Previous studies showed that the Beta (B.1.351) and Mu (B.1.621) A c c e p t e d M a n u s c r i p t 10 variants are least susceptible to sera from COVID-19 vaccine recipients [5, 16] . Our study showed that neutralizing antibodies generated by BNT162b2 and Coronavac vaccines are much less effective in neutralizing the Omicron variant than the Beta variant. Therefore, Omicron may be associated with a higher risk of breakthrough infection for COVID-19 vaccine recipients, or reinfection among recovered COVID-19 recipients. Indeed, preliminary data from South Africa suggest that the emergence of Omicron variant is associated with a higher risk of reinfection [9] . The Omicron variant carries important spike mutations that are present in both Beta (K417N, N501Y) and Delta (T478K) variants. The Omicron variant also contains the E484A mutation, which is located within the epitope recognized by clinically approved monoclonal antibodies bamlanivimab and casirivimab [21, 22] , and E484A has been shown to escape neutralization by antibody [23] . Our previous study showed that RBDs carrying E484K have lowest binding with antibodies in serum from vaccinees or from natural COVID-19 patients [5] . Furthermore, Omicron variant also carries G446S and Q493R. Mutations at spike amino acid residue 446 and 493 have been shown to affect the binding of monoclonal antibodies or from convalescent donor polyclonal serum IgG [24, 25] . The effect of other mutations are less well-defined. It remains to be determined which are the critical amino acid residues that confer reduced susceptibility. COVID-19 vaccines can also induce neutralizing antibodies that target the spike protein NTD and S2 region [26] . The Omicron variant contains several mutations in these regions. Our previous studies show that mutations in these domains can affect the neutralizing activities [6] . Whether these novel mutations affect the neutralizing activity remains to be determined. There are several limitations in this study. First, we assessed serum specimens that were collected 56 days after the first dose of vaccine. Since antibody waning is well reported [27] , it is likely that the neutralization antibody titer and seropositive rate would be lower for A c c e p t e d M a n u s c r i p t 11 serum collected longer after the vaccination. Second, this study only included adult vaccine recipients. Since the antibody titer can be higher among adolescents and children, studies in the pediatric age group would be required. Third, we have not assessed the T cell immunity against the Omicron variant, which correlates with disease severity. Fourth, since all Coronavac recipients had an MN titer of <10 against the Omicron variant and the GMT against the ancestral virus is only 21.73, an accurate fold-reduction in neutralizing antibody titer cannot be determined. In conclusion, the reduced susceptibility of Omicron variant to vaccine-induced neutralizing antibody, together with the rapid spread of this variant, suggests that newer generation vaccines should be designed to cover this variant. Preliminary study from Pfizer suggests that booster doses of BNT162b2 can enhance neutralizing antibody response against the Omicron variant [28] . Therefore booster doses should be recommended before the next generation vaccines are available. A c c e p t e d M a n u s c r i p t 12 We gratefully acknowledge the originating and submitting laboratories who contributed sequences to GISAID (Supplementary Table S1 ). This study was partly supported by the A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 20 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Nosocomial Outbreak of Coronavirus Disease 2019 by Possible Airborne Transmission Leading to a Superspreading Event Lessons learned one year after SARS-CoV-2 emergence leading to COVID-19 pandemic The World Health Organzation. COVD-19 vaccine tracker RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants Transmission of 529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19 Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic SARS-CoV-2 variants of concern and variants under investigation in England Antibody response of BNT162b2 and CoronaVac platforms in COVID-19 recovered individuals against SARS-CoV-2 wild type and delta variant A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months Omicron likely to weaken COVID vaccine protection A c c e p t e d M a n u s c r i p t 13